

Figure 1



FACS analysis of LUCA 31 and anti-EGFR antibody interactions (10ug/ml) on solid tumor cell lines
LUCA 31
? - EGFR
Mean Fluorescence
250
200
150
100
50
0
KM12
HCC-2998
HCT-15
HCT-116
LS-174T
LOVO
SW48
SW948
SW620
Colo 205
HT29
SW480
H-322M
H-226
H-23
Calu-3
Hop 62
H460
Calu-6
SKMes-1
H-522
A549
Hop 92
EKVX
Panc-1
BXPC-3
Panco 3.27
ASPc-1
HPAF-II
HS 700T
Mia Paca
Panc 2.03
SKBr-3
A431

FIGURE 2



Marker
Transferrin R
Control IgG
LUCA29
LUCA31
BER-T9
Transferrin Receptor

FIGURE 3



A
HCT15 - mAB/Luca31 competition FACS binding
(Biotinylated Luca31 concentration constant at 5ug/ml)
Mean Fluorescence
Mab concentration (ug/ml)
Luca29
Ovca18
Ovca23
Ovca26
Luca20
Kid21
42/6
BerT9
T5614
B
HCT15 - Control mAB's/Luca31 competition FACS binding
(Biotinylated Luca31 concentration constant at 5ug/ml)
Mean Fluorescence
Mab concentration (ug/ml)
Luca31
1B7.11

FIGURE 4



DNA used for Tx
CHO-pDef99
CHO-pDef99TFRC
2 ONLY
ALbUCUAS-E3D1
tdimaggio102004.001
tdimaggio102004.002
tdimaggio102004.004
tdimaggio102004.005
Counts
FL1-H
M1
2%
2%
4%
55%

FIGURE 5



HCT15 - mAB/Transferrin competition FACS binding
(mAB concentration constant at 10ug/ml)
Mean Fluorescence
200
180
160
140
120
100
80
60
40
20
0
0
20
40
60
80
100
120
Transferrin concentration (ug/ml)
Luca31
42/6
1B7.11
Ovca18
A
HCT15 - mAB/Transferrin competition FACS binding
(Alexafluor-transferrin concentration constant at 10ug/ml)
Mean Fluorescence
70
60
50
40
30
20
10
0
0
20
40
60
80
100
120
mAB Concentration (ug/ml)
Luca31
42/6
1B7.11
Ovca18
B

FIGURE 6






FIGURE 7


A
Effect of Transferrin on LUCA31: HCT1
% Inhibition
70
50
30
10
-10
-30
0
1
2
3
4
5
6
LUCA31 (ug/ml)
100ug/ml transferri
No transferri


B
Effect of Transferrin on LUCA31: HCT-116
% Inhibition
70
50
30
10
-10
-30
0
2
4
6
LUCA31 (ug/ml)
100
0



C
Effect of Transferrin on LUCA31: Lovo
% Inhibition
70
50
30
10
-10
-30
0
2
4
6
LUCA31 (ug/ml)
100
0

FIGURE 8




Untreated
Counts
0
200
400
600
800
1000
Propidium Iodide
1B7.11 (control mAb)
LUCA31
S-phase
arrested
cells
Sub-2N
content
cells

FIGURE 9

A.




B

Tumor Cell	Maximum Activity (% Inhibition) LUCA31
MDA-MB231	30
MDA-MB435	20
MCF7	70
ADR Res.	40
LNCAP	30
PC3	40

FIGURE 10

A.



B.

	Maximum Activity
Tumor Cell	LUCA31
Jurkat	90
RPMI 8226	40
HL60	90
CCRF-CEM	70
Daudi	40
K562	50

FIGURE 11



A
LUCA31 In Vitro Assay
786-O Cell Line
LUCA31
OD540
Dose (ug/mL)
B
LUCA31 In Vitro Assay
Colo205 Cell Line
LUCA31
OD540
Dose (ug/mL)
C
LUCA31 In Vitro Assay
SKMES1 Cell Line
LUCA31
OD540
Dose (ug/mL)

Figure 12



COLO205
OD(MTT)
1.6
1.4
1.2
1
0.8
0.6
0.4
0.001
0.01
0.1
1
10
MabZAP, nM
+LUCA31
-LUCA31

Figure 13



Effect of LUCA31 on leukocyte proliferation
100
80
60
40
20
0
percent inhibition
12
10
8
6
4
2
0
ug/ml of antibody
luca31
1B7

FIGURE 14



Effect of LUCA31 on cd34+ bone marrow cells
luca 31 10k cells/well
1B7 10k cells/well
luca 31 20K cells/well
1B7 20K cells/well
percent inhibition
100
80
60
40
20
0
12
10
8
6
4
2
0
ug/ml antibody

FIGURE 15



A
700
600
500
400
300
200
100
0
0 5 10 15 20 25 30 35 40 45 50 55
Vehicle
LUCA31
GEM
LUCA31 + GEM
B
1000
800
600
400
200
0
0 5 10 15 20 25 30 35 40 45 50 55
Vehicle
LUCA31
GEM
LUCA31 + GEM

FIGURE 16